DarioHealth Q2 2026 shows AI-led multi-condition momentum and stronger liquidity
Aug 11, 2026, 6:35 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The results show meaningful margin improvement and a stronger cash position, plus multi-condition ARR expansion and high-profile client wins (Fortune 50, Amwell channel). The July financing boosts liquidity, enabling investments in DarioIQ and care-delivery expansion. Investors typically reward tangible operating leverage and scalable ARR, especially when supported by high-impact partnerships and a credible path to revenue growth into 2027.
AI summary
What happened, with direct paths to the underlying reporting
DarioHealth reported Q2 2026 revenue of $5.2 million as it exits certain pharmaceutical services, with gross margin rising to 62% and a 10th straight quarter of ~80% non-GAAP B2B2C gross margins. The company also highlighted ARR of $13.1 million, more than 80% multi-condition, and a pro forma cash balance of $36.8 million after a July financing, underscoring financial flexibility to scale AI-enabled care platforms and enterprise wins into 2027.
Operating loss improved 30% YoY; expenses down 21% YoY.
Pro forma cash $36.8M after July financing; ARR $13.1M, 80% multi-condition.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
DarioHealth's CCO purchased 10,000 shares at $0.82, indicating confidence. The recent earnings report showed a GAAP earnings of 8 cents per share. Insider buying hints at positive…
